MEK inhibitor
Modulation of Antitumor Immunity by the Mek inhibitor Trametinib: Implications for Targeted Therapy of Cancer
... molecule inhibitor I tested had detrimental activity on human T cells at the concentrations required for limiting tumor cell ...approved MEK inhibitor trametinib, I found that some common γ-chain ...
163
Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development
... with MEK inhibitor AZD6244 alone only showed moderate suppression of HSC ...However, MEK inhibitor AZD6244 in combination with sorafenib synergistically inhibited HSC differentiation ...
12
Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4 RAF1 fusion
... many cancer types. In approximately 1% of melanomas, BRAF or CRAF is activated through structural arrangements. We describe a metastatic melanoma with a GOLGA4-RAF1 fusion and pathogenic variants in catenin β 1 (CTNNB1) ...
7
Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells
... following MEK inhibitor treatment appeared ...the MEK inhibitor AZD6244 stimulated phosphorylation of STAT3 mainly at Tyr705 ...approved MEK selective inhibitor trametinib, which ...
16
Trametinib: a MEK inhibitor for management of metastatic melanoma
... or MEK monotherapy due to reactivation of the MAPK pathway, what prolongs patient survival, and to reduce the cutaneous toxicity related to paradoxical activa- tion of the MAPK pathway in BRAF wild-type ...
9
Synchronous BRAFV600E and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity
... Notes: The occurrence of skin toxicity was evaluated in a Kaplan–Meier analysis for the cohort of mice. The arrow indicates the moment at which treatments were switched for the mice. representative macroscopic examples ...
10
Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
... In this case report, we present a 13-year-old boy with NRAS-mutated leptomeningeal melanocytosis in the con- text of NCM. Despite repeated surgery, the patient showed clinical progression and treatment with MEK162, a ...
7
ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells
... colon cancer. Our results showed that the combination was more effective at restraining cell proliferation (Fig. 3g, l, Additional file 2: Figure S2f) and colony formation (Fig. 3h-i, m-n). And the luciferase activity of ...
14
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
... The inhibition of the mitogen-activated protein kinases signalling pathway through combined use of BRAF and MEK inhibitors (BRAFi+MEKi) represents an established therapeutic option in patients with BRAF-mutated, ...
15
MEK inhibitors for the treatment of NRAS mutant melanoma
... selective MEK inhibitor binemetinib in the treatment of metastatic melanoma, and focus on its clinical develop- ment and describe its place in the melanoma therapeutic ...
13
Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor negative breast cancer
... and MEK inhibitor PD0325901 has a significantly higher therapeutic efficacy in reducing tumor growth, cellular proliferation and angiogenesis than monotherapy with these ...
16
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
... EGFR inhibitor Afatinib or BIBW2992, allele-specific DNAzyme cDzT with EGFR inhibitor BIBW-2992, and MAPK signaling pathway MEK inhibitor GSK1120212 combination with EGFR inhibitor ...
10
Combination treatment including targeted therapy for advanced hepatocellular carcinoma
... Based on these findings, Lim et al. reported the outcome of combination therapy with refametinib (a MEK inhibitor) plus sorafenib for Asian patients with advanced HCC [70]. In the 70 patients who received ...
16
MEK-Specific Inhibitor U0126 Blocks Spread of Borna Disease Virus in Cultured Cells
... the MEK-spe- cific inhibitor U0126, cells get infected with BDV; however, there is a block in virus spread to neighboring ...the inhibitor on virus spread was still observed when the compound was ...
7
A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
... DET1 and COP1 are regulators of MEK inhibitor response To validate the results of the genetic screen, we knocked out DET1 and COP1 in ERN1 -deficient LoVo cells. Import- antly, both in long-term assays ...
13
Inhibiting ERK Activation with CI-1040 Leads to Compensatory Upregulation of Alternate MAPKs and Plasminogen Activator Inhibitor-1 following Subtotal Nephrectomy with No Impact on Kidney Fibrosis
... by MEK plays a key role in many of the cellular processes that underlie progressive kidney fibrosis including cell proliferation, apoptosis and transforming growth factor β 1-mediated epithelial to mesenchymal ...
18
PubMedCentral-PMC4775365.pdf
... of MEK inhibition, the phosphorylation profile of MEK1/2 isoforms was analyzed in CD138 + cells obtained from 5 patients (#1, #2, #3, #4, and #9) (Figure ...the MEK inhibition of ...upon ...
20
Current and emerging treatment options for uveal melanoma
... and MEK inhibition on UM cell lines using small-molecule inhibitors, either as monotherapy or in combination with each other and the Akt ...or MEK that can be further enhanced by concurrent Akt ...to ...
14
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms
... that MEK inhibitor monotherapy with binimetinib for 4 weeks resulted in a moderate reduction of BM and spleen fibrosis similar to ruxolitinib, although with a certain variation between individual ...
17
Emerging organoid models: leaping forward in cancer research
... specific neo-antigens [58–60]. Recent advances in tumor organoids offer a promising approach to generate tumor-reactive T cells. For example, Dijkstra KK et al. performed a coculture of tumor organoids with the pa- ...
10